Search results for "RECEPTOR"

showing 10 items of 6990 documents

Erratum: By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy

2019

Basal-like breast cancer is an aggressive tumor subtype with a poor response to conventional therapies. Tumor formation and relapse are sustained by a cell subset of Breast Cancer Stem Cells (BrCSCs). Here we show that miR-100 inhibits maintenance and expansion of BrCSCs in basal-like cancer through Polo-like kinase1 (Plk1) down-regulation. Moreover, miR-100 favors BrCSC differentiation, converting a basal like phenotype into luminal. It induces the expression of a functional estrogen receptor (ER) and renders basal-like BrCSCs responsive to hormonal therapy. The key role played by miR-100 in breast cancer free-survival is confirmed by the analysis of a cohort of patients' tumors, which sho…

AdultAntineoplastic Agents HormonalTransplantation HeterologousBreast cancer basal-like differentiation miR-100Breast NeoplasmsCell Cycle ProteinsKaplan-Meier EstimateMice SCIDProtein Serine-Threonine KinasesMice Inbred NODCell Line TumorProto-Oncogene ProteinsAnimalsHumansAgedAged 80 and overReverse Transcriptase Polymerase Chain ReactionCorrectionCell DifferentiationMiddle AgedPrognosisImmunohistochemistryGene Expression Regulation NeoplasticMicroRNAsTamoxifenOncologyReceptors EstrogenMCF-7 CellsNeoplastic Stem CellsFemale
researchProduct

Effect of histamine and histamine analogues on human isolated myometrial strips.

1992

1. The effect of histamine and histamine H1- and H2-receptor agonists on isolated myometrium strips of premenopausal women has been examined. The effect of acetylcholine was also determined. 2. Histamine, 2-pyridylethylamine, 4-methylhistamine and acetylcholine, but not dimaprit, produced a concentration-related contractile response in human isolated myometrial strips. Histamine also produced a further contraction in human isolated myometrial strips precontracted with KCl (55 mM). 3. The contractile response to histamine was antagonized by the histamine H1-receptor antagonist, clemizole (0.1 microM) but was potentiated by the histamine H2-receptor antagonist, ranitidine (10 microM). Clemizo…

AdultAtropinemedicine.medical_specialtyPyridinesMuscle RelaxationHistamine H1 receptorRanitidineHistamine agonistPotassium ChlorideHistamine Agonistschemistry.chemical_compoundHistamine receptorUterine ContractionHistamine H2 receptorInternal medicinemedicineHumansPharmacologyDose-Response Relationship DrugMethylhistaminesMuscle SmoothMiddle AgedDimapritAcetylcholineClemizoleEndocrinologyMuscle relaxationchemistryMyometriumBenzimidazolesFemaleHistamineHistamineResearch ArticleBritish journal of pharmacology
researchProduct

Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study

2020

Objective To explore the glucagon-like peptide-1 analogue liraglutide in the hospital setting in patients with type 2 diabetes mellitus (T2DM) and acute coronary syndrome and to evaluate the safety and efficacy and its impact on hospitalization and short-term glycemic variability (GV). Methods A 12-week, open-label, prospective, randomized pilot clinical study with parallel groups that compared liraglutide (group 1) with glargine (group 2) and its impact on glycemic control and GV. Results Thirteen patients were included. During hospitalization, mean glucose was 164.75 mg/dL (standard deviation [SD] 19.94) in group 1 and 166.69 mg/dL (38.22) in group 2. GV determined by CV and SD was 20.98 …

AdultBlood GlucoseMaleAcute coronary syndromemedicine.medical_specialtyProspective Clinical Research ReportMedicine (General)Hospital settingtype 2 diabetes mellitusGLP-1 receptor agonistInsulin Glargine030209 endocrinology & metabolismPilot Projects030204 cardiovascular system & hematologyHypoglycemiaBiochemistryacute coronary syndrome03 medical and health sciencesRandom Allocation0302 clinical medicineR5-920Internal medicineMedicineHumansHypoglycemic AgentsInsulinGlycemic variabilityGlucagon-like peptide 1 receptorGlycemicGlycated Hemoglobinliraglutidebusiness.industryInsulin glargineLiraglutideBiochemistry (medical)Type 2 Diabetes MellitusCell BiologyGeneral MedicineMiddle Agedmedicine.diseaseHypoglycemiaMetforminDiabetes Mellitus Type 2Glycemic IndexSpainFemalebusinessmedicine.drugJournal of International Medical Research
researchProduct

Lack of plasmic beta-endorphin response to a gastronomic meal in healthy humans.

1991

Abstract In order to study the relationship between the endogenous opiate system and food intake in man, plasma concentrations of beta-endorphin were measured in ten healthy subjects. Time course of beta-endorphinemia was compared under the following conditions: basal (fasting), after an injection of pentagastrin (6 μg/kg), or after a gastronomic meal. No changes in plasma beta-endorphin or ACTH concentrations were observed with pentagastrin nor after the meal, despite the combination of very high sensory pleasure with intake of a very large amount of food. It is concluded that blood beta-endorphin concentration is not a sensitive index of the effects of food intake on the endogenous opioid…

AdultBlood GlucoseMaleendocrine systemmedicine.medical_specialtyHungerAppetiteExperimental and Cognitive PsychologyPeptide hormoneBehavioral Neurosciencechemistry.chemical_compoundEatingInternal medicinemedicineHumansPalatabilityEndogenous opioidMealbusiness.industrydigestive oral and skin physiologybeta-EndorphinPentagastrinAffectEndocrinologychemistryBasal (medicine)TasteReceptors Opioidbeta-EndorphinOpiatebusinessArousalEnergy Intakehormones hormone substitutes and hormone antagonistsmedicine.drugPhysiologybehavior
researchProduct

Insulin sensitivity and secretion and adipokine profile in patients with Cushing’s disease treated with pasireotide

2018

Purpose: To evaluate the effect of pasireotide on β-cell and adipose function in patients with Cushing’s disease (CD). Methods: Clinical and hormonal parameters, insulin secretion evaluated by HOMA-β and by the area under the curve (AUC2h) of C-peptide during a mixed meal tolerance test and insulin sensitivity, evaluated by the euglycaemic hyperinsulinaemic clamp, were evaluated in 12 patients with active CD, before and after 6 and 12 months of pasireotide. In addition, a panel of adipokines including leptin (Ob), leptin/leptin receptor ratio (Ob/Ob-R ratio), adiponectin, resistin, visfatin, adipocyte fatty acid binding protein (AFABP) and non-esterified fatty acids (NEFAs) was evaluated at…

AdultBlood GlucoseMalemedicine.medical_specialtyDiabetes mellituInjections SubcutaneousEndocrinology Diabetes and MetabolismAdipose tissueAdipokine030209 endocrinology & metabolism030204 cardiovascular system & hematologySettore MED/13 - EndocrinologiaCohort StudiesYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyAdipokinesInternal medicineDiabetes mellitusAdipokinemedicineHumansInsulinPituitary ACTH HypersecretionLeptin receptorAdiponectinbusiness.industryLeptinBody WeightMiddle AgedCushing’s diseasemedicine.diseaseInsulin sensitivityHormonesPasireotidePasireotideTreatment OutcomeEndocrinologychemistryFemaleResistinInsulin ResistanceSomatostatinbusiness
researchProduct

Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population.

2004

We investigated the association of C1431T and Pro12Ala polymorphisms at the peroxisome proliferator-activated receptor γ (PPARγ) locus with plasma lipids and insulin resistance-related variables, according to diabetes status, in a large and representative Asian population from Singapore consisting of 2,730 Chinese, 740 Malays, and 568 Indians. Moreover, we estimated the diabetes risk and examined gene-nutrient interactions between these variants and the ratio of polyunsaturated fatty acid to saturated fat (SFA) in determining body mass index (BMI) and fasting insulin. We found differential effects of these gene variants. The Pro12Ala polymorphism was more associated with plasma lipids and f…

AdultBlood GlucoseMalemedicine.medical_specialtyDiabetes riskAsiaSaturated fatmedicine.medical_treatmentMutation MissensePeroxisome proliferator-activated receptorLocus (genetics)QD415-436BiologyBiochemistryPolymorphism Single NucleotidepolymorphismBody Mass IndexEndocrinologyRisk FactorsfatDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumansInsulinAllelechemistry.chemical_classificationperoxisome proliferator-activated receptorInsulinFatty AcidsCell BiologyMiddle Agedmedicine.diseaseLipidsPPAR gammaEndocrinologychemistryFatty Acids UnsaturatedFemaleInsulin ResistancedietBody mass indexJournal of lipid research
researchProduct

Early administration of an immunomodulator and induction of remission in insulin-dependent diabetes mellitus

1990

A clinical trial was undertaken to determine whether intensive thymopentin administration enhances remission of insulin-dependent diabetes (IDDM) during the first year after diagnosis. Dosage with insulin was minimized with target control of blood glucose levels less than or equal to 7.8 mmol/l before meals. Remission was defined as a prolonged period after IDDM onset (not less than 3 months) characterized by a non-insulin-receiving (NIR) state in which target metabolic control was reached without administration of insulin and with a valid C-peptide response, evaluated after standard breakfast. Sixteen IDDM patients aged 12-31 years, recruited within 2 weeks of initiation of insulin therapy…

AdultBlood Glucosemedicine.medical_specialtyAdolescentmedicine.medical_treatmentImmunologyGastroenterologyInternal medicineDiabetes mellitusmedicineHumansInsulinImmunology and AllergyThymopentinChildGlycemicImmunity CellularC-Peptidebusiness.industryInsulinRemission InductionHemoglobin AReceptors Interleukin-2medicine.diseaseClinical trialTiterDiabetes Mellitus Type 1EndocrinologyChild PreschoolInsulin dependent diabetesMetabolic control analysisThymopentinbusinessmedicine.drugJournal of Autoimmunity
researchProduct

Insulin receptors and insulin sensitivity in normo and hyperinsulinemic obese patients

1985

The authors have studied insulin receptors on peripheral blood monocytes and insulin sensitivity, evaluated by simultaneous infusion of glucose, insulin and somatostatin in 10 control subjects and in 20 obese patients with normal glucose tolerance. The obese patients have been divided into two groups, normo (NO) and hyperinsulinemic (HO), according to the total insulin response during OGTT. We considered HO patients with insulin response higher than M + 2DS of controls. Obese patients showed, in comparison to the controls, a lower specific binding and higher degree of insulin resistance. The subdivision of obese patients allowed us to distinguish two groups. The first was characterized by b…

AdultBlood Glucosemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentBiologyGlucagonchemistry.chemical_compoundEndocrinologyInsulin resistanceHyperinsulinismInternal medicinemedicineHyperinsulinemiaHumansInsulinObesityGlucose tolerance testC-Peptidemedicine.diagnostic_testC-peptideInsulinGlucose Tolerance TestMiddle AgedGlucagonmedicine.diseaseReceptor InsulinInsulin receptorEndocrinologychemistrybiology.proteinInsulin ResistanceHyperinsulinismJournal of Endocrinological Investigation
researchProduct

Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count.

2002

Abstract Introduction: Platelet-rich plasma contains autologous thrombocyte growth factors and might be promising for acceleration of dentoalveolar bone regeneration. In this study, it was analysed for platelet counts and growth factor concentrations. Material and method: Platelet-rich plasma was isolated by discontinuous cell separation from 158 healthy men and 55 women aged 17–62 years. One hundred and fifteen specimens (stratified for age and gender of the donor) were analysed for growth factor concentrations and platelet count. Results: The platelet count in platelet-rich plasma (1,407,640±320,100/μl) was 5 times higher than in donor blood (266,040±60,530/μl). Platelet-derived growth fa…

AdultBlood PlateletsMalemedicine.medical_specialtyPlatelet-derived growth factorAdolescentmedicine.medical_treatmentBecaplerminPlateletpheresisBlood DonorsEnzyme-Linked Immunosorbent AssayTransforming Growth Factor beta1chemistry.chemical_compoundTransforming Growth Factor beta2Sex FactorsTransforming Growth Factor betaInternal medicineMedicineHumansPlateletInsulin-Like Growth Factor IBone regenerationGrowth SubstancesPlatelet-Derived Growth Factorbiologybusiness.industryPlatelet CountGrowth factorPlateletpheresisAge FactorsProto-Oncogene Proteins c-sisMiddle AgedEndocrinologyOtorhinolaryngologychemistryPlatelet-rich plasmabiology.proteinSurgeryFemaleOral SurgerybusinessGelsPlatelet-derived growth factor receptorTransforming growth factorJournal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
researchProduct

Quantification of thrombocyte growth factors in platelet concentrates produced by discontinuous cell separation.

2002

Platelet concentrates (PC) are increasingly used to increase bone regeneration in pre-prosthetic surgery. Although it is generally appreciated that certain growth factors (PDGF, TGF, EGF, and ECGF) are present in thrombocyte preparations, relatively little is known about these components in quantitative terms. The study reported here analysed the amounts of growth factors in PC produced under standard conditions from healthy volunteers. All the blood samples (237 in total) were analysed using Quantikine ELISA kits (R and D). The mean +/- SD platelet count in whole blood from these donors was 262,000+/-58,000/microl, while in PC produced by discontinuous cell separation it was 1.419,000+/-33…

AdultBlood PlateletsMalemedicine.medical_specialtyPlatelet-derived growth factorTime Factorsmedicine.medical_treatmentClinical BiochemistryBecaplerminEnzyme-Linked Immunosorbent AssayCell SeparationTransforming Growth Factor beta1chemistry.chemical_compoundInsulin-like growth factorTransforming Growth Factor beta2EndocrinologySex FactorsTransforming Growth Factor betaInternal medicinemedicineHumansPlateletInsulin-Like Growth Factor IBone regenerationGrowth SubstancesWhole bloodAgedPlatelet-Derived Growth FactorChromatographybiologyChemistryGrowth factorCell BiologyProto-Oncogene Proteins c-sisMiddle AgedEndocrinologyPlatelet-rich plasmabiology.proteinFemalePlatelet-derived growth factor receptorGrowth factors (Chur, Switzerland)
researchProduct